Literature DB >> 9220315

B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8+ T cells.

T Komata1, R Tanaka, K Yamamoto, T Oda, K Ono, S Yoshida, M Takahashi.   

Abstract

To obtain more effective cytotoxic T lymphocytes (CTLs), we examined the effect of B7 costimulation and interleukin-12 (IL-12) on the induction of allogeneic CTLs. Peripheral blood lymphocytes (PBLs) or positively selected human CD8+ T cells (purity > 99%) from healthy donors were used as effector cells, and B7-1-transfected or nontransfected U251 human glioma cells (U251-B7 or U251-Vec.) were used as stimulator cells. In mixed lymphocyte culture (MLC) with PBLs and U251 cells, nonspecific natural killer (NK) activity was raised by addition of IL-12, and the effect of B7 costimulation was not observed. However, in MLC with CD8+ T cells, efficient proliferation, generation of CTLs, and cytokine production were induced by MLC with U251-B7 in the presence of IL-12. Efficient generation of CTLs was not induced by either MLC with U251-B7 alone or the addition of IL-12 alone. Our results indicate that a combination of B7-1 costimulation and IL-12 is effective for inducing generation of CTLs, and that the CD8+ T cells can be differentiated into CTLs without the help of CD4+ T cells or antigen-presenting cells or both.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220315     DOI: 10.1097/00002371-199707000-00002

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  2 in total

1.  Recombinant adenoviral vector expressing human wild-type p53, GM-CSF, and B7-1 genes suppresses the growth of glioma in vivo.

Authors:  Sizhe Feng; Song Han; Dongsheng Pan; Mingpei Liu; Xinli Feng; Tao Dong; Wei Li; Xuezhong Wei
Journal:  Tumour Biol       Date:  2014-01-10

2.  Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor.

Authors:  Jun Morioka; Koji Kajiwara; Koichi Yoshikawa; Makoto Ideguchi; Tetsuya Uchida; Yoshinori Ohmoto; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.